Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Oraxol in Breast Cancer
NCT04993040Phase 1Completed
- Sponsor
- Athenex
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel + encequidar in breast cancer, sponsored by Athenex. Primary endpoints: Maximum Plasma Concentration at Week 4, Minimum Plasma Concentration at Week 4 and 3 more. Started Apr 2019; status: completed.
02
Drugs
paclitaxel + encequidar
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04993040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993040.